Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haimiao Yang

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Expert Opinion on Drug Metabolism & Toxicology|August 12, 2022
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Zhenyue Gao, Wei Yang, et al.
Expert Review of Clinical Pharmacology|March 8, 2023
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trialZhongnan Xu, Zhengzhi Liu, Yanli Wang, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 21, 2024
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjectsZhengzhi Liu, Jinling Xue, Qiaohuan Deng, et al.
International Immunopharmacology|April 23, 2022
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Zhengzhi Liu, et al.
Journal of Cancer Research and Clinical Oncology|June 30, 2022
A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif<sup>®</sup> in healthy Chinese subjectsGuangwen Liu, Jinling Xue, Yanli Wang, et al.
Expert Opinion on Investigational Drugs|April 15, 2022
A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Guangwen Liu, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Expert Opinion on Drug Metabolism & Toxicology|August 12, 2022
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjectsZhengzhi Liu, Zhenyue Gao, Wei Yang, et al.
Expert Review of Clinical Pharmacology|March 8, 2023
Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trialZhongnan Xu, Zhengzhi Liu, Yanli Wang, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 21, 2024
Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjectsZhengzhi Liu, Jinling Xue, Qiaohuan Deng, et al.
International Immunopharmacology|April 23, 2022
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Zhengzhi Liu, et al.
Journal of Cancer Research and Clinical Oncology|June 30, 2022
A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif<sup>®</sup> in healthy Chinese subjectsGuangwen Liu, Jinling Xue, Yanli Wang, et al.
Expert Opinion on Investigational Drugs|April 15, 2022
A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjectsZhongnan Xu, Yanli Wang, Guangwen Liu, et al.
Pageof 3